×
About 9,715 results

ALLMedicine™ Malignant Melanoma Center

Research & Reviews  3,139 results

FLI-1/Melan-A dual stain is an alternative to PRAME in differentiating metastatic melan...
https://doi.org/10.1111/cup.14373
Journal of Cutaneous Pathology; Zengin HB, Yildiz B et. al.

Dec 2nd, 2022 - Melanocytic nevi existing in lymph nodes create a diagnostic challenge by mimicking metastases. PRAME immunohistochemical stain can differentiate one from another. FLI-1 IHC expression has been shown in malignant melanoma with variable sensitivity...

Characterization and dynamics of the soluble immunological microenvironment in melanoma...
https://doi.org/10.1186/s13014-022-02167-3
Radiation Oncology (London, England); Oertel M, Borrmann K et. al.

Nov 30th, 2022 - Malignant melanoma constitutes an aggressive tumor of the skin, the pathogenesis of which is influenced by immunological processes. In this context, the influence of radiotherapy (RT) on inflammatory markers has not been studied in detail, yet. In...

Metastatic Melanoma Involving a Genetically Confirmed Angiofibroma of Soft Tissue: A Pr...
https://doi.org/10.1111/cup.14366
Journal of Cutaneous Pathology; Short EL, Logan SJ et. al.

Nov 27th, 2022 - Tumor-to-tumor metastases are an uncommon phenomenon and are very rare in the context of malignant melanoma. This case report describes a 73-year-old male who underwent an excision of a melanoma from his forehead. Six months later, he developed me...

Massively parallel reporter assays and variant scoring identified functional variants a...
https://doi.org/10.1016/j.ajhg.2022.11.006
American Journal of Human Genetics; Long E, Yin J et. al.

Nov 25th, 2022 - The most recent genome-wide association study (GWAS) of cutaneous melanoma identified 54 risk-associated loci, but functional variants and their target genes for most have not been established. Here, we performed massively parallel reporter assays...

Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685258
Journal for Immunotherapy of Cancer; Stirling ER, Terabe M et. al.

Nov 24th, 2022 - CD47 is an integral membrane protein that alters adaptive immunosurveillance when bound to the matricellular glycoprotein thrombospondin-1 (TSP1). We examined the impact of the CD47/TSP1 signaling axis on melanoma patient response to anti-PD-1 the...

see more →

Guidelines  3 results

Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhib...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534137/
Cancers (Basel); Haist M, Stege H et. al.

Oct 12th, 2021 - The advent of immune checkpoint inhibitors (ICI) improved the prognosis for patients with advanced melanoma. However, many patients do not benefit from ICI therapy due to primary and acquired resistance. Observations in murine systems suggested th...

Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cance...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882649
International Journal of Clinical Oncology; Saito T, Tabata T et. al.

Nov 22nd, 2017 - Vulvar cancer and vaginal cancer are relatively rare tumors, and there had been no established treatment principles or guidelines to treat these rare tumors in Japan. The first version of the Japan Society of Gynecologic Oncology (JSGO) guidelines...

Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment an...
https://doi.org/10.1093/annonc/mdn100
Annals of Oncology : Official Journal of the European Soc... Dummer R, Hauschild A et. al.

May 9th, 2008 - Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.|2008|Dummer R,Hauschild A,Jost L, ,|diagnosis,epidemiology,pathology,therapy,diagnosis,epidemiology,pathology,therapy,

see more →

Drugs  13 results see all →

Clinicaltrials.gov  335 results

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT02133196

Oct 14th, 2022 - Background: Patients with metastatic non-small cell lung cancer (NSCLC) have few approved therapeutic options and those that exist are of transient benefit. Recent clinical experiences with experimental agents that release checkpoints on the host ...

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
https://clinicaltrials.gov/ct2/show/NCT02973789

Oct 14th, 2022 - PAST PRE-CLINICAL AND CLINICAL EXPERIENCE: The effect of the electric fields (TTFields, TTF) has demonstrated significant activity in in vitro and in vivo NSCLC pre-clinical models both as a single modality treatment and in combination with chemot...

Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma
https://clinicaltrials.gov/ct2/show/NCT00199901

Oct 12th, 2022 - NY-ESO-1 protein is an immune target found in many cancers including melanoma. ISCOMATRIX® adjuvant enhances immune responses. This trial compares NY-ESO-1 ISCOMATRIX® vaccine with ISCOMATRIX® adjuvant alone to assess whether treatment with NY-ESO...

Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma
https://clinicaltrials.gov/ct2/show/NCT02410733

Oct 7th, 2022 - The Lipo-MERIT vaccine consists of four naked ribonucleic acid (RNA)-drug products (DPs) that are optimized to induce antigen-specific cluster of differentiation (CD)8+ and CD4+ T cell responses against the four selected malignant melanoma-associa...

Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT05479812

Oct 5th, 2022 - This is a first-in-human, Phase I, open-label, multicenter study designed to evaluate the safety, tolerability and preliminary efficacy of WTX-124, a conditionally-activated IL-2 prodrug, when administered as monotherapy and in combination with pe...

see more →

News  393 results

FDA Grants Fast Track Designation to KIN-2787 for Select Stage IIB to IV Malignant Melanoma
https://www.onclive.com/view/fda-grants-fast-track-designation-to-kin-2787-for-select-stage-iib-to-iv-malignant-melanoma

Sep 26th, 2022 - The FDA has granted a fast track designation to KIN-2787 for use as a potential therapeutic option in patients with BRAF class II or III alteration–positive and/or NRAS mutation–positive, metastatic or unresectable, stage IIB to IV malignant melan...

Dual Checkpoint Blockade Holds Promise as Long-term Treatment Option in NSCLC
https://www.onclive.com/view/dual-checkpoint-blockade-holds-promise-as-long-term-treatment-option-in-nsclc

Aug 19th, 2022 - Biomarker selection has played a crucial role in the rapid advancement of clinical benefit observed for patients with non–small cell lung cancer (NSCLC). At the time of diagnosis of advanced lung cancer molecular testing is imperative and the best...

Discrepancies in Skin Cancer Screening Reporting Among Patients, Primary Care Physicians, and Patient Medical Records
https://www.mdedge.com/dermatology/article/256904/melanoma/discrepancies-skin-cancer-screening-reporting-among-patients
Natalie H. Matthews, MD, MPhil, Augustine W. Kang, PhD et. al.

Aug 9th, 2022 - Keratinocyte carcinoma (KC), or nonmelanoma skin cancer, is the most commonly diagnosed cancer in the United States. 1 Basal cell carcinoma comprises the majority of all KCs.

Cilta-cel Produces Durable Responses in Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/cilta-cel-produces-durable-responses-in-relapsed-refractory-multiple-myeloma

Aug 1st, 2022 - A single infusion of the CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel; Carvykti) produced deep and durable responses in patients with relapsed/refractory multiple myeloma with a manageable toxicity profile, according to long-term follow...

A Revolution Is Pending for Real-World Data Use in Cancer Care
https://www.onclive.com/view/a-revolution-is-pending-for-real-world-data-use-in-cancer-care

Aug 1st, 2022 - In the opinion of this commentator, one of the more exciting developments in clinical investigation over the past several years is the increasing recognition of the importance of real-world data and its role for physicians, regulators, policy make...

see more →

Patient Education  3 results see all →